Related Experiment Videos
Pharmacologic regression of cardiac hypertrophy in experimental hypertension
Insights
Cardiac hypertrophy may not fully reverse with blood pressure medication alone. Secondary cardiorenal and neurohumoral changes can influence heart mass, even when hypertension is pharmacologically controlled.
Area of Science:
- Cardiovascular Physiology
- Cardiac Remodeling
- Hypertension Research
Background:
- The heart can adapt its mass to hemodynamic and metabolic demands.
- Established cardiac hypertrophy, such as in hypertensive heart disease, raises questions about reversibility.
- Reversal of left ventricular weight is variable when hypertension is controlled pharmacologically versus stimulus removal.
Purpose of the Study:
- To investigate whether augmented cardiac mass in established hypertensive heart disease can revert to normal with arterial pressure control.
- To explore the influence of pharmacologic pressure reduction on left ventricular weight.
- To examine potential secondary adjustments in cardiorenal and neurohumoral function affecting cardiac hypertrophy.
Main Methods:
- Review of experimental models of induced systemic hypertension in genetically normotensive animals.
- Comparison of left ventricular weight changes following removal of the hypertension stimulus versus pharmacologic pressure reduction.
- Analysis of secondary cardiorenal and neurohumoral adjustments in response to pharmacologic therapy.
Main Results:
- In experimental models, removal of the hypertension stimulus generally restores normal left ventricular weight.
- Pharmacologic control of arterial pressure, with the inciting stimulus intact, yields more variable results on ventricular weight.
- Pharmacologic pressure reduction may trigger secondary cardiorenal and neurohumoral changes impacting cardiac hypertrophy.
Conclusions:
- Reversal of cardiac hypertrophy is less predictable with pharmacologic blood pressure control compared to removing the underlying cause.
- Secondary cardiorenal and neurohumoral adaptations appear to play a significant role in modulating ventricular mass during pharmacologic hypertension management.
- Further research is needed to understand these complex interactions and optimize treatment strategies for hypertensive heart disease.
Abstract:
The normal heart has the capacity to either augment or reduce its mass in relation to long-term alterations in hemodynamic and metabolic demands. However, once cardiac hypertrophy is established, as in hypertensive heart disease, it is less clear whether the augmented mass can revert to normal with control of arterial pressure. In experimental models in which systemic hypertension is induced in genetically normotensive animals, left ventricular weight generally returns toward normal with the removal of the inciting stimulus for the hypertension. However, when arterial pressure control is achieved by pharmacologic therapy, and the inciting stimulus (mechanical or genetic) is intact, the results of pressure reduction on ventricular weight are much more variable than that observed with the removal of a mechanical stimulus for hypertension. It is hypothesized that pharmacologic pressure reduction elicits secondary adjustments in cardiorenal and neurohumoral function which have important influences on ventricular hypertrophy.